These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36998013)

  • 1. The impact of impaired sleep quality on symptom change and future exacerbation of chronic obstructive pulmonary disease.
    Lin L; Song Q; Duan J; Liu C; Cheng W; Zhou A; Peng Y; Zhou Z; Zeng Y; Chen Y; Cai S; Chen P
    Respir Res; 2023 Mar; 24(1):98. PubMed ID: 36998013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical characteristics and outcomes of different inhaled therapies in chronic obstructive pulmonary disease patients with frequent cough.
    Li X; Song Q; Cheng W; Liu C; Lin L; Li J; Peng Y; Zeng Y; Yi R; Liu Y; Li X; Chen Y; Cai S; Chen P
    Ann Med; 2023; 55(2):2304107. PubMed ID: 38233371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population.
    Liu D; Song Q; Zeng Y; Yi R; Liu Y; Li X; Chen Y; Cai S; Chen P
    Int J Chron Obstruct Pulmon Dis; 2023; 18():1741-1751. PubMed ID: 37599897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
    Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
    Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Effectiveness of Inhalation Therapy Among Patients With Symptomatic COPD in China: A Multicenter Prospective Study.
    Cheng W; Duan J; Zhou A; Zhao Y; Yi R; Liu Y; Deng D; Li X; Zeng Y; Peng Y; Song Q; Lin L; Yang M; Chen P
    Front Pharmacol; 2021; 12():753653. PubMed ID: 34621178
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S; Dell'Aniello S; Ernst P
    Lancet Respir Med; 2018 Nov; 6(11):855-862. PubMed ID: 30343028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ; Price D; Anzueto A; Singh D; Altman P; Bader G; Patalano F; Fogel R; Kostikas K
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V; Corhay JL; Germonpré P; Janssens W; Joos GF; Liistro G; Vincken W; Gurdain S; Vanvlasselaer E; Lehouck A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of switching from triple therapy to dual bronchodilation in COPD: the DACCORD 'real world' study.
    Vogelmeier CF; Worth H; Buhl R; Criée CP; Gückel E; Kardos P
    Respir Res; 2022 May; 23(1):109. PubMed ID: 35501806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical characteristics and treatment response of patients with chronic obstructive pulmonary disease with low body mass index.
    Song Q; Zhou A; Lin L; Li X; Cheng W; Liu C; Peng Y; Zeng Y; Yi R; Liu Y; Li X; Chen Y; Cai S; Chen P
    Front Pharmacol; 2023; 14():1131614. PubMed ID: 37521460
    [No Abstract]   [Full Text] [Related]  

  • 13. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A; Montes de Oca M; Menezes AM; Wehrmeister FC; Lopez Varela MV; Mendoza L; Ramírez L; Miravitlles M
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1545-1556. PubMed ID: 29785104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study.
    Suissa S; Dell'Aniello S; Ernst P
    COPD; 2021 Feb; 18(1):1-8. PubMed ID: 33569990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
    Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting muscarinic antagonist versus long-acting β2 agonist/corticosteroid for moderate to severe chronic obstructive pulmonary disease patients: Exacerbation risk assessment.
    Yang SN; Ko HK; Hsiao YH; Su KC; Chang YL; Huang HY; Perng DW; Chung MI
    J Chin Med Assoc; 2019 Jun; 82(6):488-494. PubMed ID: 31180947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
    Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
    Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.